Download and citation
Suggested citation
Supplement Brief. Clinical Dose Registry dataset, v26. Retrieved 2026-11-14, from https://supplementbrief.com/dataset/clinical-doses.json. Licensed CC BY 4.0. Market medians derived from the NIH Office of Dietary Supplements Dietary Supplement Label Database. Versioned records, one address each, are at /data/v1/.
What is inside each entry
- Ingredient display name, form, and elemental fraction where relevant
- Studied dose range with unit and per-day normalization
- Trial floor: the dose the pivotal trials actually used, with a PMID or DOI anchor
- Evidence level and outcome direction
- Trial-floor funding: industry, mixed, independent, or not stated, with the funder named when a company paid
- NIH DSLD market medians: median label dose and the share of products at or above the trial floor
Trial floor funding
Each trial floor is tagged from the paper that set it. Industry and mixed name the funder. A company payment is disclosed here and stays on the floor.
54 of 54 trial floors
Depression trial in Parkinson's disease (50 mg/day)
Antidepressant add-on (300 mg/day)
Obesity trial (900 mg/day)
Stress and cortisol RCT (Chandrasekhar 2012)
Dose-ranging trial (Salve 2019)
Adiposity RCT (Lei 2026, MASLD)
Weight meta-analyses (1 g/day and up)
Cochrane weight review (pooled doses)
Pittler 2003 sensitivity analysis
Verisol skin trials (branded peptide)
Generic hydrolyzed collagen (instrumental skin trials)
Maintenance (postmenopausal + training meta-analyses)
Two-year bone trial dose (research)
GLP-1 / weight-loss lean-mass context
Example at 70 kg (1.2–1.6 g/kg)
Aged garlic extract RCT (Ried 2018)
Standardized EGb 761 extract (Kang 2002)
900 mg open-label pilots (historical only)
Typical trial dose (anchor, not meta mean)
Cochrane weight-loss review
Dose-response meta (Lin 2020)
1000 mg three times daily (de Andrade 2007)
900 mg three times daily (Hong 2002)
Cochrane pooled estimate (effect rated trivial)
Menafra 2022 (vasculogenic ED)
Cormio 2011 pilot (mild ED)
Antidepressant-induced sexual dysfunction, women
Dose-finding pilot, 1.5 g arm failed
Men with mild ED, subjective wellbeing
Daily value (women)
Daily value (men)
Form-comparison trial (elemental)
Bisglycinate sleep trial (elemental)
Cognition and sleep trial (compound weight)
Delayed sleep-wake phase disorder, 0.5 mg timed
Circadian phase advance, timing over dose
NAD+ elevation trial (1000 mg/day)
OTC inflammatory-marker meta-analyses (EPA+DHA)
EPA dose-finding in inflammatory depression
REDUCE-IT (prescription icosapent ethyl)
US OTC pill limit (FDA)
Chronic constipation meta-analysis (response threshold)
Weight-loss meta-analysis (mean dose, before meals)
Statin-intolerant RCT (Becker 2009)
Fluoxetine-related sexual dysfunction, men
Fluoxetine-related sexual dysfunction, women
Postpartum depression, saffron vs fluoxetine
Depression meta-analyses (pooled)
ATLAS trial, branded Mitopure
Older adults, 1000 mg
Safety and mitochondrial gene signature
Endothelial function trial (1000 mg)
Oral repletion (deficiency confirmed)
Typical multivitamin (not therapeutic)
Ingredients in this release
Changelog
November 6, 2026
Trial floors on this page can be filtered by funding. Industry and mixed rows name the funder. The JSON download already carried the field.
September 13, 2026
Registry counts 19 published entries; this dataset page ships with license, citation, and changelog surfaces.
September 10, 2026
Batch 2 briefed for physician review (ashwagandha, ginkgo, potassium ceiling, red yeast rice, aged garlic) — entries ship after sign-off.